Gilead Sciences, Inc.

About Gilead Sciences, Inc.

Gilead Sciences is a biopharmaceutical company focused on delivering transformative therapies and advancing health equity. Their mission is to build a healthier world for all people through innovation, combating devastating diseases, and ensuring access to medicines globally.

Products & Services

Medicines:Over 25 medicines offered globally across various therapeutic areas.

Clinical Programs:52 clinical programs spanning Virology, Oncology, and Inflammation.

Specialties

Virology (HIV, Viral Hepatitis, COVID-19, and Emerging Viruses) Oncology Inflammation Clinical Trials Health Equity Global Health Access Virology HIV programs Health equity

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 3000000000 MR: - FA: $3 billion FAN: 3000000000	D: 2026-05-14 FD: 2026-05-14	3 investors
2	RT: Debt T: - FT: Debt	A: 3500000000 MR: - FA: 3.5 billion FAN: 3500000000	D: 2024-11-13 FD: 2024-11-13	2 investors

Debt Latest

2026-05-14

$3.0B

3 investors (Pro only)

Debt 2024-11-13

$3.5B

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Daniel O’Day

Chairman and Chief Executive Officer, Gilead Sciences

D

Dietmar Berger

Chief Medical Officer

A

Andrew Dickinson

Chief Financial Officer

S

Stacey Ma

Executive Vice President, Pharmaceutical Development and Manufacturing

F

Flavius Martin

Executive Vice President, Research

J

Jyoti Mehra

Executive Vice President, Human Resources

View 15 more team members with Pro

Unlock Full Team Directory

Recent News